Gene and Protein Information
Species	TM	AA	Chromosomal Location	Gene Symbol	Gene Name	Reference
Plasmodium falciparum 3D7	-	874		GWT1	GPI-anchored wall transfer protein 1, putative

Previous and Unofficial Names

GWT1 | Pf3D7_06_v3:627,693..630,345(-) | PFF0740c

Database Links
Alphafold	C6KSZ4 (Pf3D7)
PlasmoDB	PF3D7_0615300 (Pf3D7)
UniProtKB	C6KSZ4 (Pf3D7)

Whole Organism Assay Data Linked to This Target
Key to terms and symbols		Click column headers to sort
Ligand Sp. Assay description Type Action Value Parameter Reference compound VII [WO2021149692A1] Pf3D7 Plasmodium falciparum 3D7 P. falciparum strain 3D7 (Pf3D7) was derived from isolate NF54 by limiting dilution. The complete genome of Pf3D7 has been sequenced (GenBank: LN999946.1). Pf3D7 can be obtained from the European Malaria Reagent Repository or the Malaria Research and Reference Reagent Resource Center (MR4) and is sensitive to a panel of antimalarial compounds including chloroquine and pyrimethamine. ✖ Parasite growth inhibition assay - - 7.5 pIC50 2 ⤷ pIC50 7.5 (IC50 3x10-8 M) Parasite lactate dehydrogenase (pLDH ) assay following 72 hours in culture [2] Lifecycle stages: Plasmodium asexual blood stage (erythrocytic merozoite, trophozoite, erythrocytic schizont) compound VII [WO2021149692A1] PfK1 Plasmodium falciparum K1 P. falciparum strain K1 (PfK1) was isolated in Kanchanaburi, Thailand in 1979. PfK1 can be obtained from the European Malaria Reagent Repository or the Malaria Research and Reference Reagent Resource Center (MR4) and is reported to be a multidrug-resistant strain. ✖ Parasite growth inhibition assay - - 7.4 pIC50 2 ⤷ pIC50 7.4 (IC50 4.1x10-8 M) Parasite lactate dehydrogenase (pLDH ) assay following 72 hours in culture [2] Lifecycle stages: Plasmodium asexual blood stage (erythrocytic merozoite, trophozoite, erythrocytic schizont)

Malaria Pharmacology Comments

GWT1 (PfGWT1), one of the essential enzymes involved in glycosylphosphatidylinositol (GPI) biosynthesis in the malaria parasite P. falciparum, is a promising novel target for antimalarial drug development (Patent WO2004048567 [1]). In this patent representative compounds known to inhibit yeast GWT1 were assayed for antimalarial activity, with compound 3 (PubChem CID 9860834) reported to have the most potent activity.